Kavita Juneja
Corcept Therapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kavita Juneja as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:03 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06947304 · Evaluation of Miricorilant on Liver Fat in Patients With MASLDCorcept Therapeutics · completed · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) · study director
- Ph2NCT06108219 · A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)Corcept Therapeutics · completed · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) · study director
- N/ANCT05320146 · A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)Corcept Therapeutics · completed · Nonalcoholic Steatohepatitis (NASH) · study director
- Ph1NCT05117489 · A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)Corcept Therapeutics · completed · Nonalcoholic Steatohepatitis (NASH) · study director
- Ph2NCT04524403 · A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)Corcept Therapeutics · completed · Antipsychotic-induced Weight Gain (AIWG) · study director
- Ph2NCT03818256 · A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsCorcept Therapeutics · completed · Antipsychotic-induced Weight Gain (AIWG) · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:03 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.N Engl J Med · 2022996 citationsRCR 74.3
- SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.J Infect Dis · 202413 citationsRCR 1.2
- Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants.Clin Transl Sci · 20238 citationsRCR 0.6
- Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.Clin Transl Sci · 20237 citationsRCR 0.5